A study published in the British Medical Journal indicates that GLP-1 agonist medications, such as Ozempic, may significantly lower alcohol-related hospitalizations. Researchers from the University of Washington analyzed data from over 40,000 adults with a history of alcoholism to determine the efficacy of these drugs.
The 65% Drop in Hospitalizations for Obese Patients
According to the report published in the British Medical Journal,indiviudals using GLP-1 agonists experienced a substantial decrease in emergency admissions for alcohol-related issues. Specifically, obese patients who were already receiving treatment for drinking problems saw a 65% reduction in hospitalizations when they were also prescribed GLP-1 drugs. This suggests that the medication provides a protective layer that standard addiction therapies may lack.
The University of Washington study also highlighted significant benefits for those with type 2 diabetes. In this group, GLP-1 users had a 63% lower risk of alcohol-related hospitalization compared to those on conventional alcohol addiction medications. Even when compared to other standard diabetes treatments, the GLP-1 jabs were associated with up to a 26% lower risk of hospitalization.
Modulating the Brain's Reward System via GLP-1
The mechanism behind these results lies in how drugs like Ozempic, Wegovy (semaglutide), and Mounjaro (tirzepatide) interact with the body. These medications mimic the GLP-1 hormone, which suppresses appetite, but they also appear to modulate the brain's reward system. Because the same neural pathways govern both overeating and substance addiction, the drugs may effectively curb alcohol cravings.
This finding aligns with a broader trend of research into the neurological effects of semaglutide. As reported in a 2025 JAMA Psychiatry study, semaglutide reduced overall alcohol consumption by 40% and lowered cravings. Other early research suggests these medications could potentially reduce the risk of addiction to cigarettes and illicit drugs by as much as 25%, positioning GLP-1s as a potential systemic tool for behavioral modification.
England's £27 Billion Burden and the US Death Toll
The potential repurposing of these drugs comes at a time of critical public health need. In the United States, excessive alcohol use is responsible for over 178,000 deaths annually. Meanwhile, in England, the societal and economic cost of alcohol abuse is estimated to exceed £27 billion per year, creating a massive incentive for the healthcare system to find more effective intervention methods.
There are slight signs of improvement in the UK, where alcohol-specific deaths declined from a record high of 10,473 in 2023 to 9,809 in 2024. However, with 1.6 million people already using weight-loss jabs in the UK, the scale of adoption for GLP-1 drugs could accelerate this downward trend if they are officially approved for addiction treatment .
Why Dr. Marie Spreckley Demands Rigorous Clinical Trials
Despite the promising numbers , medical experts warn against premature adoption. Dr. Marie Spreckley of the University of Cambridge notes that while observational evidence is growing, the medical community requires more rigorous, controlled trials before GLP-1s can be officially recommended for alcohol use disorder. The current data is observational,meaning researchers could not fully control for the varying severity of the participants' addictions.
Currently, a significant gap exists between clinical potential and legal prescription. The NHS cannot prescribe GLP-1 drugs for addiction, and private prescriptions remain limited to those classified as severely overweight. Until definitive evidence from controlled clinical trials is established, the use of Ozempic or Mounjaro for alcoholism remains an off-label possibility rather than a standard of care.
Comments 0